Kinetics and mechanism of a macrocyclic chromium(III) complex oxidation to chromium(IV) by hexacyanoferrate(III) in strongly alkaline media

Oxidation of the macrocyclic Cr(III) complex cis-[Cr(cycb)(OH)(2)](+), where cycb = rac-5,5,7,12,12,14-hexamethyl-1,4,8,11-tetraazacyclotetradecane, by an excess of the hexacyanoferrate( III) in basic solution, slowly produces Cr(V) species. These species, detected using e.p.r. spectroscopy, are stable under ambient conditions for many hours, and the hyperfine structure of the e.p.r. spectrum is consistent with the interaction of the d-electron with four equivalent nitrogen nuclei. Electro-spray ionization mass spectrometry suggests a concomitant oxidation of the macrocyclic ligand, in which double bonds and double bonded oxygen atoms have been introduced. By comparison basic chromate(III) solutions are oxidized rapidly to chromate(VI) by hexacyanoferrate(III) without any detectable generation of stable Cr(V) intermediates.

Electron impact excitation of the Fe-peak ions Ni III and Ni IV

Accurate determination of electron excitation rates for the Fe-peak elements is complicated by the presence of an open 3d-shell in the description of the target ion, which can lead to hundreds of target state energy levels. Furthermore, the low energy scattering region is dominated by series of Rydberg resonances, which require a very fine energy mesh for their delineation. These problems have prompted the development of a suite of parallel R-matrix codes. In this work we report recent applications of these codes to the study of electron impact excitation of Ni III and Ni IV.

OXYGEN CATALYSIS BY ANHYDROUS RUTHENIUM(IV) OXIDE

The results of a kinetic study of the oxidation of water to oxygen by Ce(IV) ions in different acid media, mediated by anhydrous ruthenium(IV) oxide are described. In an acid medium which is predominantly HClO4 the kinetics are diffusion controlled and first order with respect to both [Ce(IV)] and [RuO2] and exhibit an activation energy of 19 kJ mol-1. In 0.5 mol dm-3 H2SO4 the kinetics are much slower and complex, the rate decreasing with increasing [Ce(III)]. The kinetics of catalysis observed in all the different acid media studied are readily interpreted using an electrochemical model in which the catalyst particles are considered as acting as microelectrodes which mediate electron transfer between a Nernstian reduction reaction (Ce(IV) --> Ce(III)) and an irreversible oxidation reaction (H2O --> 2H+ + 1/2O2). This electrochemical model is used to analyse the complex kinetics observed in 0.5 mol dm-3 H2SO4 and extract mechanistic information concerning the nature of the rate determining step.

Immune-derived PD-L1 gene expression defines a subgroup of stage II/III colorectal cancer patients with favorable prognosis that may be harmed by adjuvant chemotherapy

A recent phase 2 study of metastatic colorectal carcinoma (CRC) patients showed that mismatch repair gene status was predictive of clinical response to PD-1-targeting immune checkpoint blockade. Further examination revealed strong correlation between PD-L1 protein expression and microsatellite instability (MSI) in stage IV CRC, suggesting that the amount of PD-L1 protein expression could identify late stage patients who may benefit from immunotherapy. To assess whether the clinical associations between PD-L1 gene expression and MSI identified in metastatic CRC are also present in stage II/III CRC, we used in silico analysis to elucidate the cell types expressing the PD-L1 gene. We found a significant association of PD-L1 gene expression with MSI in early stage CRC (P < 0.001) and show that unlike in non-CRC tumors, PD-L1 is derived predominantly from the immune infiltrate. We demonstrate that PD-L1 gene expression has positive prognostic value in the adjuvant disease setting (PD-L1low v PD-L1high HR = 9.09; CI, 2.11-39.10). PD-L1 gene expression had predictive value, as patients with high PD-L1 expression appear to be harmed by standard-of-care treatment (HR = 4.95; CI,1.10-22.35). Building on the promising results from the metastatic CRC PD-1-targeting trial, we provide compelling evidence that PD-L1high/MSI/immunehigh stage II/III CRC patients should not receive standard chemotherapy. This conclusion supports the rationale to clinically evaluate this patient subgroup for PD-1 blockade treatment.